Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications?

D H Manier1, R C Shelton, F Sulser

  • 1Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37232-2647, USA.

Abstract

Insights

Neurotransmitter signals converge on the transcription factor CREB in human fibroblasts, demonstrating protein kinase cross-talk. This finding explains how antidepressant drugs influence gene expression and may enhance clinical efficacy.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Neuroscience

Background:

  • Investigates the hypothesized cross-talk between neurotransmitter transduction cascades.
  • Focuses on protein kinase-mediated phosphorylation of the nuclear transcription factor CREB in human fibroblasts.

Purpose of the Study:

  • To confirm or refute the cross-talk hypothesis involving CREB phosphorylation.
  • To elucidate the role of protein kinase A (PKA) and protein kinase C (PKC) pathways in CREB phosphorylation.

Main Methods:

  • Human fibroblasts were treated with isoproterenol (activates PKA) and/or phorbol 12-myristate 13-acetate (PMA, activates PKC).
  • Nuclear CREB phosphorylation (CREB-P) was determined using immunoblotting, enhanced chemiluminescence, and laser densitometry.

Main Results:

  • Both isoproterenol and PMA stimulated CREB phosphorylation.
  • The phosphorylation induced by both pathways was additive and occurred at serine133 of CREB.
  • Confirmed cross-talk at the level of protein kinase-mediated phosphorylation of transcription factors.

Conclusions:

  • The convergence of neurotransmitter signals via CREB phosphorylation is a critical mechanism in gene expression.
  • This mechanism may explain the efficacy of antidepressant drugs targeting noradrenergic and serotonergic pathways.
  • Provides a rationale for the clinical effectiveness of dual uptake inhibitors.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).